In Brief: Adac Labs
This article was originally published in The Gray Sheet
Executive Summary
Adac Labs: Firm's MCD/ACTM (Molecular Coincidence Detection with Attenuation Correction) technology receives 510(k) clearance, permitting the firm to add the distortion-reducing feature to its nuclear medicine imaging systems. By correcting for "image distortions created by non-uniform attenuation of soft tissue in the human body," MCD/ACTM permits Adac's systems to perform both single photon emission computed tomography and coincidence imaging, the company explains...
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.